Kura Oncology (KURA) Enterprise Value Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.78% |
| Dec 31, 2025 | -1.05% |
| Sep 30, 2025 | -11.05% |
| Jun 30, 2025 | -13.23% |
| Mar 31, 2025 | -24.85% |
| Dec 31, 2024 | -25.15% |
| Sep 30, 2024 | -12.73% |
| Jun 30, 2024 | -13.46% |
| Mar 31, 2024 | -26.07% |
| Dec 31, 2023 | -18.82% |
| Sep 30, 2023 | -19.28% |
| Jun 30, 2023 | -30.53% |
| Mar 31, 2023 | -24.05% |
| Dec 31, 2022 | -36.29% |
| Sep 30, 2022 | -33.52% |
| Jun 30, 2022 | -53.26% |
| Mar 31, 2022 | -52.01% |
| Dec 31, 2021 | -50.18% |
| Sep 30, 2021 | -48.77% |
| Jun 30, 2021 | -47.94% |
| Mar 31, 2021 | -52.07% |
| Dec 31, 2020 | -49.17% |
| Sep 30, 2020 | -51.16% |
| Jun 30, 2020 | -49.14% |
| Mar 31, 2020 | -32.28% |
| Dec 31, 2019 | -191.58% |
| Sep 30, 2019 | -397.59% |
| Jun 30, 2019 | -781.27% |
| Mar 31, 2019 | -668.68% |
| Dec 31, 2018 | -671.04% |
| Sep 30, 2018 | -607.40% |
| Jun 30, 2018 | -482.91% |
| Mar 31, 2018 | -762.17% |
| Dec 31, 2017 | -620.36% |
| Sep 30, 2017 | -610.03% |
| Jun 30, 2017 | -462.19% |
| Mar 31, 2017 | -377.85% |
| Dec 31, 2016 | -593.70% |
| Sep 30, 2016 | -555.64% |
| Jun 30, 2016 | -512.97% |
| Mar 31, 2016 | -606.45% |
| Dec 31, 2015 | -401.99% |
| Sep 30, 2015 | -611.96% |